Procare Diagnostics is dedicated to developing novel prostate cancer diagnostic technologies, utilizing a new urinary biomarker, which has the potential to be more accurate than other common prostate cancer markers in detecting and monitoring prostate cancer, as well as guiding therapy.

We will be using this novel biomarker to develop a prostate cancer diagnostic technology that will improve detection when compared to existing tests and facilitate early and appropriate therapeutic intervention.

Our vision is to provide men all over the world with a more accurate prostate cancer diagnostic test that will enable better detection and hopefully improve prognosis.

With enhanced specificity and sensitivity, we hope to reduce the number of needless biopsies, confirm negative biopsies, and lead to better patient management, thereby improving lives.